While cost-effectiveness studies for GLP-1 drugs for diabetes, obesity, and cardiovascular + obesity indications continue to emerge, their high out-of-pocket costs create a significant financial burden on individual patients [22,131,132,133]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.